| Methods |
Participants were randomized to ibuprofen 600 mg, 3 times daily, starting 4 hours before ascent, or acetazolamide 125mg, twice daily, started the night before rapid ascent from 1240 m to 3810 m during summer 2017 in the White Mountains of California |
| Participants |
Healthy adult volunteers living at low altitude |
| Interventions |
ibuprofen 600 mg, 3 times daily, starting 4 hours before ascent; or acetazolamide 125 mg, twice daily, started the night before rapid ascent |
| Outcomes |
The main outcome measure was AMS incidence the night after ascent, measured by the Lake Louise Questionnaire (LLQ), with a score of > 3 with headache and 1 other symptom. Sleep quality was assessed with the Groningen Sleep Quality Survey (GSQS) and headache severity through a modified visual analogue scale (mVAS) |
| Notes |
Related to systematic review Nieto 2017 . Conference proceeding only (January 2019) |
